Vania Tietsche de Moraes Hungria

Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma

Edvan de Queiroz Crusoé, Glaciano Ribeiro, João Tadeu Damian Souto Filho, Jayr Schmidt Filho et autres

br, ar, es (code pays fourni par la source)

Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS

Sonja Zweegman, Saad Z. Usmani, Vania Tietsche de Moraes Hungria, Nizar Jacques Bahlis et autres

Daratumumab, lenalidomide, and dexamethasone (DRd) is approved to treat transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) based on the phase 3 MAIA trial [ 1 , 2 , 3 ]. Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) is approved to treat patients …

nl, us, br, ca, cz, es, gb, il, jp, fr, pl (code pays fourni par la source)

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas

Efstathios Kastritis, Shaji Kunnathu Kumar, S. Vincent Rajkumar, Wee Joo Chng et autres

Solitary plasmacytomas (SPs) are rare localized tumors of clonal plasma cells, either in the bone (solitary bone plasmacytoma) or in soft tissue/extraosseous (extramedullary) with either no or with minimal bone marrow (BM) infiltration (<10% clonal plasma cells by immunohistochemistry) and no evidence …

gr, us, sg, de, br, is, fr, es, ca, gb, kr, it (code pays fourni par la source)

Criteria for referring pediatric and adult patients with hematological diseases to palliative care: Consensus of the Brazilian Association of Hematology, hemotherapy and cell therapy (2025)

Amanda Pifano Soares Ferreira, Cecília Emerick Mendes Vaz, Laura Ferreira de Mesquita Ferraz, Paulo de Mello Novita Teixeira et autres

Palliative care is, according to the World Health Organization (WHO), "a global ethical responsibility" and crucial to person-centered healthcare, for the relief of physical and psychological symptoms and social and spiritual suffering, impacting the improvement of the quality of life not only …

br (code pays fourni par la source)

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

João Tadeu Damian Souto Filho, Lucas Oliveira Cantadori, Edvan de Queiroz Crusoé, Vania Tietsche de Moraes Hungria et autres

Frontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has advanced with anti-CD38 monoclonal antibody (mAb)-based regimens. Although quadruplet combinations incorporating daratumumab and isatuximab have demonstrated improved response rates and progression-free survival (PFS), comparative overall survival (OS) data remain limited. We performed …

br (code pays fourni par la source)

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

Suzanne Trudel, Vania Tietsche de Moraes Hungria, María‐Victoria Mateos, Chee Paul Lin et autres

Abstract Background: In DREAMM-7 (NCT04246047), belantamab mafodotin (belamaf) in combination with bortezomib and dexamethasone (BVd) demonstrated significant improvements in progression-free survival (PFS; median follow-up, 28.2 months; hazard ratio [HR], 0.41; 95% CI, 0.31-0.53; P<0.001) and overall survival (median follow-up, 39.4 months; HR, …

ca, br, es, us, gb, kr, gr, jp (code pays fourni par la source)

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Jin Lu, Albert Oriol, Alejandro Berkovits, Andrew G Spencer et autres

Abstract Introduction: IRAKLIA is an international, open-label, non-inferiority (NI) trial (NCT05405166) investigating isatuximab (Isa) subcutaneous (SC) vs intravenous (IV) administration, plus pomalidomide-dexamethasone (Pd) and the first Phase 3 multiple myeloma (MM) trial using an on-body injector (OBI). IRAKLIA demonstrated NI in its …

cn, es, cl, au, gb, it, cz, pl, ar, gr, hu, tr, us, br, fr (code pays fourni par la source)

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: A network meta-analysis and reconstructed individual patient data meta-analysis

João Tadeu Damian Souto Filho, Lucas Oliveira Cantadori, Edvan de Queiroz Crusoé, Vania Tietsche de Moraes Hungria et autres

Abstract Introduction: Frontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has evolved significantly. Although triplet regimens have long constituted the standard of care, recent quadruplet combinations incorporating anti-CD38 monoclonal antibodies (mAb), daratumumab and isatuximab, have demonstrated improved response rates and progression-free …

br (code pays fourni par la source)

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Peter Michael Voorhees, Meletios Athanasios Dimopoulos, Yael Chava Cohen, Fredrik Hellem Schjesvold et autres

Abstract Introduction : Current standard of care for smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), is observation until progression to active MM. Increasing evidence suggests that patients (pts) with SMM at high risk for progression to active MM …

us, gr, il, no, br, ca, gb, au, jp, nl, tr, es, hu, ar, be, cz, dk, it, se, de (code pays fourni par la source)

Venous thromboembolism in multiple myeloma patients treated with BCMA-directed CAR T-cell therapy: A systematic review and meta-analysis

Javier Marco, Thays Ferraz Soares, Mohammed Abbas Baghdadi, Patrick Van Dreden et autres

Abstract Background. Multiple myeloma (MM) ia associated with a 7–9-fold higher risk of venous thromboembolism (VTE) than the general population. IMiD-based regimens historically reported VTE rates up to 26% during induction and >50% in some combinations. The MELISSE study found a 15.5% …

fr, es, br, gr, us (code pays fourni par la source)

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study

Nizar Jacques Bahlis, Jeffrey A. Zonder, Lionel Karlin, Torben Plesner et autres

Daratumumab-based regimens demonstrate clinical efficacy in relapsed/refractory multiple myeloma (RRMM). As more patients receive frontline daratumumab-based therapy, evaluation of daratumumab retreatment is needed. In the phase 2 LYNX study (ClinicalTrials.gov Identifier: NCT03871829), 88 patients with RRMM who received 1–3 prior lines of …

ca, us, fr, dk, it, pl, br, de, be, gr, kr, Gabon, nl, il, cn (code pays fourni par la source)

TREATMENT PATTERNS AND OUTCOMES IN THE SECOND AND THIRD LINES AND AFTER TRIPLE-CLASS EXPOSURE: SUBANALYSIS OF THE LATIN AMERICAN MULTIPLE MYELOMA REGISTRY STUDY (MYLACRE)

A Maiolino, K Galvez, G Remaggi, Natalia Paola Schutz et autres

Patterns of care for multiple myeloma (MM) vary across countries. MYLACRE was a non-interventional registry of patients (pts) diagnosed with MM between in Latin America. We analyzed MYLACRE pts treated in the 2nd and 3rd lines of therapy (LOT2 and LOT3), with …

br, co, ar, pe (code pays fourni par la source)